RAD51 anticorps (AA 1-134)

N° du produit ABIN7868106

L’anticorps anti-RAD51 Monoclonal Souris est utilisé pour la détection de RAD51 dans des échantillons de Humain. Il a été validé pour WB, FACS et IHC (p).

Aperçu rapide pour RAD51 anticorps (AA 1-134) (ABIN7868106)

Antigène: RAD51 (DNA Repair Protein Homolog 1 (RAD51))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp RAD51 est non-conjugé

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: RAD51-2701

Détail du produit anti-RAD51 anticorps

Épitope: AA 1-134

Fonction: RAD51 Antibody (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogène: A portion of amino acids 1-134 from the human protein was used as the immunogen for this RAD51 antibody.

Isotype: IgG2b, kappa

Information d'application

Indications d'application: Optimal dilution of the RAD51 antibody should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the RAD51 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Détails sur RAD51

Antigène: RAD51 (DNA Repair Protein Homolog 1 (RAD51))

Autre désignation: RAD51

Sujet: RAD51 is one of the key factors of DNA repair by homologous recombination and has been shown to have anti-apoptotic activity in tumor cells. RAD51 protein interacts with a variety of tumor suppressor proteins including p53, BRCA1 and BRCA2. Elevated expression of RAD51 enhances radio-resistance of human tumor cells. Overexpression of RAD51 protein in tumor cells renders them resistant against cytotoxic drugs like Cisplatin. RAD51 interacts with BRCA1 and BRCA2 to influence subcellular localization and cellular response to DNA damage. BRCA2 inactivation may be a key event leading to genomic instability and tumorigenesis from deregulation of RAD51. High-level expression of RAD51 has been observed in a variety of human malignancies. RAD51 overexpression correlates with histological grading of the tumor in invasive ductal mammary carcinoma.

UniProt: Q06609

Pathways: Réparation de l'ADN